losartan has been researched along with aliskiren in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (27.27) | 29.6817 |
| 2010's | 32 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jensen, C; Nussberger, J; O'Brien, E; Stanton, A | 1 |
| Conroy, RM; Dicker, P; Fitzgerald, D; Moore, N; O'Brien, ET; O'Brien, JK; Shields, D; Stanton, AV; Stojanovic, M; Treumann, A | 1 |
| Deswal, A; Mann, DL; Ramasubbu, K | 1 |
| Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F | 1 |
| Ingelfinger, JR | 1 |
| Damodar, A; Panesar, M | 1 |
| Lindner, T | 1 |
| Anderson, S; Komers, R | 1 |
| Appelbaum, E; Berglund, T; Cherif Papst, C; Dahlöf, B; Lukashevich, V; Manning, WJ; Smith, BA; Solomon, SD; Verma, A | 1 |
| Ellrichmann, G; Gaupp, S; Gold, R; Kvakan, H; Lee, DH; Linker, RA; Manzel, A; Muller, DN; Rump, LC; Seubert, S; Stegbauer, J | 1 |
| Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J | 1 |
| Chan, CM; Wong, KS; Woo, KT | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E | 1 |
| Suzuki, H; Takenaka, T | 1 |
| Cervenka, L; Husková, Z; Kramer, HJ; Vaněčková, I; Vaňourková, Z | 1 |
| Cervenka, L; Husková, Z; Kramer, HJ; Kujal, P; Mrázová, I; Rakusan, D; Thumová, M; Vanecková, I; Vanourková, Z; Vernerová, Z | 1 |
| Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F; Rossing, P | 2 |
| Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Zoppi, A | 1 |
| Filler, G; Kelland, EE; McAuley, LM | 1 |
| Handler, J | 1 |
| Au, WS; Ho, YW; Lai, KN; Lin, M; Ma, MK; Tam, S; Tang, SC; Yap, DY | 1 |
| Appelbaum, E; Dahlöf, B; Desai, A; Lukashevich, V; Pouleur, AC; Prescott, MF; Smith, BA; Solomon, SD; Uno, H | 1 |
| Balakrishnan, A; Cassis, LA; Charnigo, R; Daugherty, A; Howatt, DA; Liau, G; Lu, H; Wu, C | 1 |
| Appelbaum, E; Dahlof, B; Pouleur, AC; Prescott, M; Smith, B; Solomon, SD; Takeuchi, M; Vardeny, O; Verma, A | 1 |
| Casarini, DE; Castro, MM; Ceron, CS; Costa-Neto, CM; Gerlach, RF; Guimaraes, D; Martins-Oliveira, A; Oliveira, DM; Reis, RI; Ribeiro, AA; Rizzi, E; Tanus-Santos, JE | 1 |
| Baucke, J; Danser, AH; Divac, N; Fraune, C; Frenay, AR; Garrelds, IM; Hölzel, A; Jankowski, V; Krebs, C; Lange, S; Nguyen, G; Schwedhelm, E; Stahl, R; Streichert, T; van Goor, H; Velden, J; Wenzel, UO | 1 |
| Aguila, MB; Batista, Tde M; Frantz, ED; Mandarim-de-Lacerda, CA; Penna-de-Carvalho, A | 1 |
| Anantharaman, V; Chan, CM; Choong, HL; Foo, M; Fook-Chong, S; Lee, EJ; Lee, GS; Tan, HK; Wong, KS; Woo, KT | 1 |
| Haque, S; Kasinath, BS; Kumar, V; Lederman, R; Malhotra, A; Rai, P; Rehman, S; Sataranatrajan, K; Singhal, PC | 1 |
| Hsu, CN; Huang, LT; Lee, CT; Tain, YL | 1 |
| Creazzo, M; Dalbeni, A; Dattilo, G; Imbalzano, E; Lizio, G; Mandraffino, G; Saitta, A; Sardo, MA; Scarpelli, M; Tomasello, C; Trapani, G | 1 |
| Buchneva, NV; Kuz'min, OB; Landar', LN | 1 |
| Andress, DL; Bijlsma, MJ; de Zeeuw, D; Heerspink, HJ; Kröpelin, TF; Parving, HH; Persson, F | 1 |
| Becerril, C; Checa, M; Díaz-Piña, G; García de Alba, C; Montes, E; Ordoñez-Razo, R; Páramo, I; Ruiz, V; Vega, A | 1 |
| Adhikari, S; Alpert, L; Bissonnette, M; Chen, L; Deb, DK; Dougherty, U; Hart, J; He, L; Kwon, J; Li, YC; Liu, SQ; Liu, T; Liu, W; Pekow, J; Rubin, DT; Shi, Y; Wang, J; Zhao, Q; Zhou, G | 1 |
| Buchneva, NV; Kuzmin, OB; Landar, LN | 1 |
| Andreotti, S; Caminhotto, Rde O; Campaãa, AB; Lima, FB; Sertié, RA | 1 |
| Biedunkiewicz, B; Chamienia, AL; Debska-Slizien, AM; Heleniak, Z; Lizakowski, S; Małgorzewicz, S; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L | 1 |
| Fu, J; Liu, T; Shi, Y; Xing, Y; Xue, X; Yao, L; Zhao, X | 1 |
| Casarini, DE; Ceron, CS; Fernandes, FB; Guimaraes, DA; Martins-Oliveira, A; Oliveira, DMM; Pinheiro, LC; Rizzi, E; Tanus-Santos, JE; Tirapelli, CR | 1 |
| Augusto, MJ; Elias Júnior, J; Parreira, NA; Prado, CM; Ramalho, FS; Ramalho, LNZ; Rodrigues, V; Silva, DM | 1 |
| Bispo-da-Silva, LB; Coelho Balbi, AP; de Morais, RB; do Couto Muniz, VP; Filho, SRF; Nakamura Hiraki, KR; Nunes Costa, E | 1 |
4 review(s) available for losartan and aliskiren
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Anti-angiotensin therapy: new perspectives.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Fumarates; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Clinical trials of the past decade in the management of chronic kidney disease.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Combined Modality Therapy; Drug Therapy, Combination; Fumarates; Humans; Hypercholesterolemia; Hypertension; Kidney Failure, Chronic; Losartan; Proteinuria; Renal Replacement Therapy | 2009 |
[Recent clinical evidences of RAS inhibitors on chronic kidney diseases].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Kidney Diseases; Losartan; Tetrazoles; Valine; Valsartan | 2010 |
11 trial(s) available for losartan and aliskiren
| Article | Year |
|---|---|
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
Topics: Administration, Oral; Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fumarates; Humans; Hypertension; Losartan; Male; Middle Aged; Patient Compliance; Renin | 2003 |
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Female; Fumarates; Humans; Hypertension; Losartan; Male; Middle Aged; Multivariate Analysis; Proteinuria; Renin | 2008 |
Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Topics: Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Echocardiography; Female; Fumarates; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome | 2009 |
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fumarates; Humans; Kidney Diseases; Kidney Function Tests; Losartan; Male; Middle Aged | 2010 |
Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure; Female; Fibrinolysis; Fumarates; Humans; Hypertension; Insulin; Losartan; Male; Metabolic Syndrome; Middle Aged; Young Adult | 2010 |
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Fumarates; Humans; Hypertension, Renal; Losartan; Male; Middle Aged; Placebos; Treatment Outcome | 2011 |
Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study.
Topics: Adult; Amides; Antihypertensive Agents; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Fumarates; Glomerulonephritis, IGA; Hong Kong; Humans; Interleukin-6; Kidney Function Tests; Losartan; Male; Middle Aged; Odds Ratio; Pilot Projects; Prospective Studies; Proteinuria; Risk Assessment; Severity of Illness Index; Time Factors; Transforming Growth Factor beta; Treatment Outcome; Urinalysis | 2012 |
Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
Topics: Aldosterone; Amides; Antihypertensive Agents; Blood Pressure; Demography; Female; Fumarates; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Organ Size; Systole | 2011 |
Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.
Topics: Aldosterone; Amides; Antihypertensive Agents; Biomarkers; Blood Pressure; Diabetes Complications; Female; Fumarates; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Organ Size; Renin; Treatment Outcome | 2012 |
Aliskiren and losartan trial in non-diabetic chronic kidney disease.
Topics: Amides; Blood Pressure; Comorbidity; Demography; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fumarates; Glomerular Filtration Rate; Humans; Hyperkalemia; Losartan; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Systole | 2014 |
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.
Topics: Aged; Albuminuria; Amides; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Female; Fumarates; Humans; Hypertension; Losartan; Male; Potassium; Ramipril; Systole | 2015 |
29 other study(ies) available for losartan and aliskiren
| Article | Year |
|---|---|
Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition.
Topics: Adult; Aged; Amides; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chi-Square Distribution; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Fumarates; Genetic Predisposition to Disease; Haplotypes; Humans; Hypertension; Linear Models; Losartan; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Renin; Renin-Angiotensin System; Severity of Illness Index; Treatment Outcome | 2007 |
Aliskiren and dual therapy in type 2 diabetes mellitus.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Fumarates; Humans; Losartan; Proteinuria; Renin; Renin-Angiotensin System | 2008 |
Aliskiren combined with losartan in diabetes and nephropathy.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Drug Therapy, Combination; Fumarates; Humans; Losartan; Proteinuria; Renin; Telmisartan | 2008 |
Aliskiren combined with losartan in diabetes and nephropathy.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Losartan; Mineralocorticoid Receptor Antagonists; Proteinuria; Renin; Spironolactone | 2008 |
Aliskiren combined with losartan in diabetes and nephropathy.
Topics: Amides; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Fumarates; Humans; Losartan; Proteinuria; Renin; Renin-Angiotensin System | 2008 |
Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antigen-Presenting Cells; Cell Movement; Cells, Cultured; Chemokines; Enalapril; Encephalomyelitis, Autoimmune, Experimental; Fumarates; Losartan; Mice; Mice, Inbred C57BL; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Fumarates; Health Care Costs; Humans; Hypertension; Irbesartan; Losartan; Quality-Adjusted Life Years; Tetrazoles | 2009 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Synergism; Fumarates; Kidney Glomerulus; Losartan; Male; Mice; Mice, Inbred C57BL; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2010 |
Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Down-Regulation; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Fumarates; Hypertension; Kidney; Losartan; Male; Mice; Pilot Projects; Radioimmunoassay; Rats; Rats, Transgenic; Renin; Time Factors | 2010 |
Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats.
Topics: Amides; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Models, Animal; Fumarates; Heart Rate; Hypertension; Kidney Glomerulus; Losartan; Male; Proteinuria; Rats; Rats, Transgenic; Renin; Time Factors | 2010 |
Are we ready to use aliskiren in children?
Topics: Adolescent; Age Factors; Amides; Angiotensin II Type 1 Receptor Blockers; Child, Preschool; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fumarates; Humans; Kidney Diseases; Losartan; Male; Off-Label Use; Patient Selection; Proteinuria; Renin; Renin-Angiotensin System; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
Managing erectile dysfunction in hypertensive patients.
Topics: Amides; Antihypertensive Agents; Benzopyrans; Chlorthalidone; Ethanolamines; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Impotence, Vasculogenic; Losartan; Male; Middle Aged; Nebivolol; Risk Factors | 2011 |
Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Atherosclerosis; Blood Pressure; Cholesterol; Diet, High-Fat; Enalapril; Fumarates; Hypercholesterolemia; Kidney; Losartan; Male; Mice; Mice, Knockout; Receptor, Angiotensin, Type 1; Receptors, LDL; Renin; Renin-Angiotensin System | 2012 |
Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling.
Topics: Amides; Animals; Antihypertensive Agents; Aorta; Fumarates; Hypertension; Losartan; Male; Random Allocation; Rats; Rats, Wistar; Treatment Outcome; Ventricular Remodeling | 2013 |
AT1 antagonism and renin inhibition in mice: pivotal role of targeting angiotensin II in chronic kidney disease.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Dose-Response Relationship, Drug; Fumarates; Gene Expression; Kidney; Losartan; Male; Mice; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Treatment Outcome | 2012 |
Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice.
Topics: Adipose Tissue; Amides; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Enalapril; Fumarates; Gene Expression Profiling; Gene Expression Regulation; Gluconeogenesis; Insulin Resistance; Leptin; Lipid Metabolism; Losartan; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Renin-Angiotensin System | 2014 |
Renin angiotensin system modulates mTOR pathway through AT2R in HIVAN.
Topics: AIDS-Associated Nephropathy; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Fumarates; HIV; Kidney Diseases; Losartan; Mice; Mice, Transgenic; Phosphorylation; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Aliskiren in early postnatal life prevents hypertension and reduces asymmetric dimethylarginine in offspring exposed to maternal caloric restriction.
Topics: Amides; Angiotensin-Converting Enzyme 2; Animals; Animals, Newborn; Arginine; Blood Pressure; Blotting, Western; Body Weight; Caloric Restriction; Female; Fumarates; Gene Expression Regulation; Histone Deacetylases; Hypertension; Losartan; Male; Peptidyl-Dipeptidase A; Rats, Sprague-Dawley | 2015 |
[Interaction of renin-angiotensin system inhibitors with dopamine in rat kidney].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Dopamine; Dopamine Agents; Fumarates; Kidney; Losartan; Male; Natriuresis; Rats; Renin-Angiotensin System; Water-Electrolyte Balance | 2014 |
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Topics: Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrasentan; Bone Density Conservation Agents; Diabetic Nephropathies; Endothelin Receptor Antagonists; Ergocalciferols; Female; Fumarates; Humans; Losartan; Male; Middle Aged; Office Visits; Pyrrolidines; Randomized Controlled Trials as Topic; Research Design; Statistics as Topic; Urine Specimen Collection | 2015 |
Profibrosing effect of angiotensin converting enzyme inhibitors in human lung fibroblasts.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Enalapril; Fibroblasts; Fibrosis; Fumarates; Humans; Losartan; Lung; Protein Biosynthesis; Renin; Transcription, Genetic; Transforming Growth Factor beta1 | 2015 |
Activation of the Renin-Angiotensin System Promotes Colitis Development.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Colitis; Colon; Epithelial Cells; Fumarates; Humans; Hydralazine; Inflammatory Bowel Diseases; Losartan; Mice; Mice, Transgenic; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Th17 Cells | 2016 |
[INTERACTION OF BETA-BLOCKER PROPRANOLOL WITH RENIN-ANGIOTENSIN SYSTEM INHIBITORS IN RAT KIDNEY].
Topics: Amides; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diuresis; Diuretics; Drug Synergism; Enalapril; Fumarates; Kidney; Losartan; Male; Natriuresis; Potassium; Propranolol; Rats; Renin-Angiotensin System; Sodium | 2016 |
Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro.
Topics: Adipocytes; Amides; Animals; Antihypertensive Agents; Captopril; Fumarates; Glucose; Glycerol; Lipogenesis; Lipolysis; Losartan; Male; Rats, Wistar; Renin-Angiotensin System | 2016 |
Aliskiren reduces albuminuria after kidney transplantation.
Topics: Adult; Aged; Albuminuria; Amides; Blood Pressure; Creatinine; Double-Blind Method; Female; Fumarates; Humans; Hypertension; Kidney Transplantation; Losartan; Male; Middle Aged | 2017 |
Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system.
Topics: Amides; Animals; Blood Pressure; Chronic Disease; Extracellular Matrix; Female; Fumarates; Losartan; Lung; Mice; Pulmonary Fibrosis; Renin-Angiotensin System; Vitamin D Deficiency | 2017 |
Direct renin inhibition is not enough to prevent reactive oxygen species generation and vascular dysfunction in renovascular hypertension.
Topics: Amides; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Drug Synergism; Fumarates; Hypertension, Renovascular; Losartan; Male; Nitrites; Oxidative Stress; Rats; Reactive Oxygen Species; Relaxation; Renin | 2018 |
The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Bradykinin; Fumarates; Lisinopril; Liver; Liver Cirrhosis; Losartan; Male; Mice; Mice, Inbred BALB C; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin; Renin-Angiotensin System; Schistosomiasis mansoni; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Vasodilator Agents | 2018 |
Mast cell population in the development of diabetic nephropathy: Effects of renin angiotensin system inhibition.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enalapril; Fumarates; Glomerular Filtration Rate; Losartan; Male; Mast Cells; Rats; Rats, Wistar; Renin-Angiotensin System | 2018 |